Preliminary report of tolvaptan treatment in japanese patients with heart failure

International Heart Journal

Volumn 53, Issue 1, 2012, Pages 72-74

  Semba, Hiroaki ^a   Kinugawa, Koichiro ^a   Takeda, Norihiko ^a   Shiga, Taro ^a   Nishimura, Go ^a   Inajima, Tsukasa ^a   Uchino, Yuichi ^a   Iwata, Hiroshi ^a   Hasumi, Eriko ^a   Abe, Hajime ^a   Terada, Yumiko ^a   Yonenaga, Akihiko ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fluid overload; Heart failure; Tolvaptan; V2 antagonist

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; CARVEDILOL; DIURETIC AGENT; ENALAPRIL; INDAPAMIDE; SPIRONOLACTONE; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DYSPNEA; HEART FAILURE; HUMAN; JAPANESE; LABORATORY TEST; LEG EDEMA; LONG TERM CARE; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; PLEURA EFFUSION; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

AGED; BENZAZEPINES; HEART FAILURE; HUMANS; JAPAN; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN;

EID: 84857811061     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.53.72     Document Type: Article

References (18)

1. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16.
2. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
3. Shiba N, Shimokawa H. Chronic heart failure in Japan: implications of the CHART studies. Vasc Health Risk Manag 2008; 4: 103-13. (Review)
4. Shiba N, Watanabe J, Shinozaki T, et al. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. Circ J 2004; 68: 427-34.
5. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345: 574-81.
6. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000; 140: 840-7.
7. Guidelines for Treatment of Acute Heart Failure (JCS 2006).
8. Ito T, Yoshimura M, Nakamura S, et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003; 107: 807-10.
9. Sato N, Kajimoto K, Asai K, et al. Acute decompensated heart failure syndromes (ATTEND) registry prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 2010; 159: 949-55.
10. Ikram H, Chan W, Espiner ER, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 1980; 59: 443-9.
11. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-85. (Review)
12. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705-8.
13. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-64.
14. Fukunami M, Matsuzaki M, Hori M, Izumi T. An open-label study of tolvaptan in heart failure patients with volume overload. J Cardiac Fail 2010; 16: S159.
15. Matsuzaki M, et al. Clinical effect of tolvaptan, an oral vasopressin V2 receptor antagonist, in patients with chronic heart failure and peripheral edema. Results from a double-blind, randomized trial. Circ J 2009; 73: 127.
16. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7.
17. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.
18. Gheorghiade M, Gattis WA, O'Conner CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.